The antitumor effects of regorafenib were then compared with those of DC-101, a murine anti-VEGFR2 antibody, in an orthotopic liver cancer model to identify possible immune modulatory effects independent of anti-VEGFR2 effects. Here, KDR is linked to liver cancer.